Roiser, JP;
Nathan, PJ;
Mander, AP;
Adusei, G;
Zavitz, KH;
Blackwell, AD;
(2015)
Assessment of cognitive safety in clinical drug development.
Drug Discovery Today
, 21
(3)
pp. 445-453.
10.1016/j.drudis.2015.11.003.
Preview |
Text
Assessment of cognitive safety in clinical drug development.pdf - Published Version Download (2MB) | Preview |
Abstract
Cognitive impairment is increasingly recognised as an important potential adverse effect of medication. However, many drug development programmes do not incorporate sensitive cognitive measurements. Here, we review the rationale for cognitive safety assessment, and explain several basic methodological principles for measuring cognition during clinical drug development, including study design and statistical analysis, from Phase I through to postmarketing. The crucial issue of how cognition should be assessed is emphasized, especially the sensitivity of measurement. We also consider how best to interpret the magnitude of any identified effects, including comparison with benchmarks. We conclude by discussing strategies for the effective communication of cognitive risks.
| Type: | Article |
|---|---|
| Title: | Assessment of cognitive safety in clinical drug development |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.drudis.2015.11.003 |
| Publisher version: | http://doi.org/10.1016/j.drudis.2015.11.003 |
| Language: | English |
| Additional information: | This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| Keywords: | Science & Technology, Life Sciences & Biomedicine, Pharmacology & Pharmacy, BLOOD-BRAIN-BARRIER, PARKINSONS-DISEASE, IMPAIRMENT, DEMENTIA, ANTICHOLINERGICS, ANTIHISTAMINES, SCHIZOPHRENIA, PERFORMANCE, DEPRESSION, MANAGEMENT |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Div of Psychology and Lang Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Div of Psychology and Lang Sciences > Institute of Cognitive Neuroscience |
| URI: | https://discovery.ucl.ac.uk/id/eprint/1480983 |
Archive Staff Only
 |
View Item |
